[{"id":"3a5c5d6a-237c-4943-9f23-41234e0aa377","acronym":"","url":"https://clinicaltrials.gov/study/NCT03755804","created_at":"2021-01-18T18:27:48.805Z","updated_at":"2025-02-25T16:37:17.115Z","phase":"Phase 2","brief_title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","source_id_and_acronym":"NCT03755804","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • bendamustine • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-07"},{"id":"c40fa03c-9c20-4928-9562-c4d2f144ca96","acronym":"DAR-UM-2","url":"https://clinicaltrials.gov/study/NCT05987332","created_at":"2023-08-14T15:10:06.767Z","updated_at":"2025-02-25T16:27:34.251Z","phase":"Phase 2/3","brief_title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","source_id_and_acronym":"NCT05987332 - DAR-UM-2","lead_sponsor":"IDEAYA Biosciences","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Xalkori (crizotinib) • Yervoy (ipilimumab) • dacarbazine • darovasertib (IDE196)"],"overall_status":"Recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 01/15/2028","study_completion_date":" 01/15/2028","last_update_posted":"2025-02-04"},{"id":"5dee7c2d-c458-4efc-8ddb-50ee403de9bf","acronym":"SGN35-015","url":"https://clinicaltrials.gov/study/NCT01716806","created_at":"2021-01-18T07:28:55.529Z","updated_at":"2024-07-02T16:34:27.249Z","phase":"Phase 2","brief_title":"A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)","source_id_and_acronym":"NCT01716806 - SGN35-015","lead_sponsor":"Seagen Inc.","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • dacarbazine • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 10/31/2012","start_date":" 10/31/2012","primary_txt":" Primary completion: 04/07/2023","primary_completion_date":" 04/07/2023","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2024-06-11"},{"id":"84dc5381-b2bd-414d-95d6-7e4b13384698","acronym":"","url":"https://clinicaltrials.gov/study/NCT01771107","created_at":"2021-01-18T07:48:13.309Z","updated_at":"2024-07-02T16:35:02.686Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma","source_id_and_acronym":"NCT01771107","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/07/2013","start_date":" 03/07/2013","primary_txt":" Primary completion: 10/15/2021","primary_completion_date":" 10/15/2021","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-17"},{"id":"1d61c822-8b23-4a8f-b429-8c238d66ec51","acronym":"HR-NBL2","url":"https://clinicaltrials.gov/study/NCT04221035","created_at":"2021-01-18T20:32:43.345Z","updated_at":"2024-07-02T16:35:03.584Z","phase":"Phase 3","brief_title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","source_id_and_acronym":"NCT04221035 - HR-NBL2","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" MYCN • MYCL","pipe":" | ","alterations":" MYCN amplification • MYCL amplification","tags":["MYCN • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dacarbazine • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • cyclophosphamide intravenous • vindesine"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 11/05/2019","start_date":" 11/05/2019","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2024-05-15"},{"id":"6a4ac4b8-ac4e-46a2-bb00-4f42aa1f1efd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01920932","created_at":"2021-01-18T08:40:01.212Z","updated_at":"2024-07-02T16:35:11.441Z","phase":"Phase 2","brief_title":"Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma","source_id_and_acronym":"NCT01920932","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 08/12/2013","start_date":" 08/12/2013","primary_txt":" Primary completion: 11/16/2020","primary_completion_date":" 11/16/2020","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-04-04"},{"id":"93a88c34-d0f2-492b-a36d-f9ea207da396","acronym":"C25004","url":"https://clinicaltrials.gov/study/NCT02979522","created_at":"2021-01-18T14:39:24.684Z","updated_at":"2024-07-02T16:35:18.840Z","phase":"Phase 1/2","brief_title":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","source_id_and_acronym":"NCT02979522 - C25004","lead_sponsor":"Takeda","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 05/05/2020","primary_completion_date":" 05/05/2020","study_txt":" Completion: 09/24/2029","study_completion_date":" 09/24/2029","last_update_posted":"2024-02-19"},{"id":"43117010-8c09-4b16-8b62-84e304e25621","acronym":"","url":"https://clinicaltrials.gov/study/NCT04893356","created_at":"2021-05-19T11:52:40.134Z","updated_at":"2024-07-02T16:35:31.135Z","phase":"","brief_title":"Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)","source_id_and_acronym":"NCT04893356","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • MGMT expression","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dacarbazine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 01/20/2025","study_completion_date":" 01/20/2025","last_update_posted":"2023-10-30"},{"id":"b53b591c-7a34-44d3-8a4e-88612967f74d","acronym":"AMC-085","url":"https://clinicaltrials.gov/study/NCT02298257","created_at":"2021-01-18T10:50:16.201Z","updated_at":"2024-07-02T16:35:35.674Z","phase":"Phase 2","brief_title":"A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma","source_id_and_acronym":"NCT02298257 - AMC-085","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 08/08/2022","study_completion_date":" 08/08/2022","last_update_posted":"2023-09-26"},{"id":"df1aef8d-1125-430b-acad-455dcf473546","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008106","created_at":"2023-08-23T15:11:11.269Z","updated_at":"2024-07-02T16:35:39.195Z","phase":"Phase 3","brief_title":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","source_id_and_acronym":"NCT06008106","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • Kolupin (tunlametinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 09/22/2027","primary_completion_date":" 09/22/2027","study_txt":" Completion: 09/22/2027","study_completion_date":" 09/22/2027","last_update_posted":"2023-08-23"},{"id":"e32acf9a-5168-4575-8fb9-1421d8e2ec35","acronym":"","url":"https://clinicaltrials.gov/study/NCT03430297","created_at":"2021-01-18T16:55:15.181Z","updated_at":"2024-07-02T16:35:39.800Z","phase":"Phase 3","brief_title":"A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT03430297","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • dacarbazine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 256","initiation":"Initiation: 02/02/2018","start_date":" 02/02/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-08-17"},{"id":"4f76cd83-e646-4932-a2d7-78e27c5572aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01868451","created_at":"2021-01-18T08:21:39.824Z","updated_at":"2024-07-02T16:35:43.603Z","phase":"","brief_title":"Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma","source_id_and_acronym":"NCT01868451","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-07-07"},{"id":"5aa9101f-5e17-4f18-aed0-af281c1f2b88","acronym":"R-2","url":"https://clinicaltrials.gov/study/NCT05898451","created_at":"2023-06-12T16:09:02.706Z","updated_at":"2024-07-02T16:35:45.921Z","phase":"Phase 2","brief_title":"Effect of Refnot on Immunity in Cancer Patients","source_id_and_acronym":"NCT05898451 - R-2","lead_sponsor":"Refnot-Pharm Ltd","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • dacarbazine • lomustine • Zadaxin (thymalfasin)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 06/04/2009","start_date":" 06/04/2009","primary_txt":" Primary completion: 11/01/2011","primary_completion_date":" 11/01/2011","study_txt":" Completion: 11/01/2011","study_completion_date":" 11/01/2011","last_update_posted":"2023-06-12"},{"id":"4b87c7c7-3bac-4f3c-931b-f9da998486ab","acronym":"BREACH","url":"https://clinicaltrials.gov/study/NCT02292979","created_at":"2021-01-18T10:48:37.178Z","updated_at":"2025-02-25T14:57:07.731Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.","source_id_and_acronym":"NCT02292979 - BREACH","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • bleomycin • vinblastine"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/02/2022","study_completion_date":" 06/02/2022","last_update_posted":"2022-08-19"},{"id":"712abef4-ee9f-449b-a706-9e273acea522","acronym":"","url":"https://clinicaltrials.gov/study/NCT00822120","created_at":"2021-01-18T03:07:31.140Z","updated_at":"2024-07-02T16:36:05.303Z","phase":"Phase 2","brief_title":"S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma","source_id_and_acronym":"NCT00822120","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 371","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 04/30/2016","primary_completion_date":" 04/30/2016","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2022-08-18"},{"id":"12bdd7c1-fcfb-4492-93a6-624b6e9c7434","acronym":"","url":"https://clinicaltrials.gov/study/NCT01835145","created_at":"2021-01-18T08:10:09.271Z","updated_at":"2024-07-02T16:36:06.016Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01835145","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • dacarbazine"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 07/31/2013","start_date":" 07/31/2013","primary_txt":" Primary completion: 10/21/2016","primary_completion_date":" 10/21/2016","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2022-08-04"},{"id":"1f0315a3-9a77-4954-9081-0bb2c991dc95","acronym":"CheckMate 066","url":"https://clinicaltrials.gov/study/NCT01721772","created_at":"2021-01-17T17:45:43.984Z","updated_at":"2024-07-02T16:36:07.444Z","phase":"Phase 3","brief_title":"Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma","source_id_and_acronym":"NCT01721772 - CheckMate 066","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • dacarbazine"],"overall_status":"Completed","enrollment":" Enrollment 418","initiation":"Initiation: 01/18/2013","start_date":" 01/18/2013","primary_txt":" Primary completion: 06/24/2014","primary_completion_date":" 06/24/2014","study_txt":" Completion: 05/14/2021","study_completion_date":" 05/14/2021","last_update_posted":"2022-07-12"},{"id":"80560848-c8eb-4834-b676-a9ac8d60e508","acronym":"PROMIT","url":"https://clinicaltrials.gov/study/NCT04225390","created_at":"2021-01-18T20:34:09.769Z","updated_at":"2024-07-02T16:36:09.761Z","phase":"Phase 2","brief_title":"Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy","source_id_and_acronym":"NCT04225390 - PROMIT","lead_sponsor":"University of Erlangen-Nürnberg Medical School","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dacarbazine"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/13/2020","start_date":" 01/13/2020","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2022-05-27"},{"id":"065ca1e7-873c-4b91-a2b2-4b85d4aa8b0a","acronym":"CheckMate 037","url":"https://clinicaltrials.gov/study/NCT01721746","created_at":"2021-01-18T07:30:46.124Z","updated_at":"2024-07-02T16:36:12.116Z","phase":"Phase 3","brief_title":"A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)","source_id_and_acronym":"NCT01721746 - CheckMate 037","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600 • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600 • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • carboplatin • paclitaxel • dacarbazine"],"overall_status":"Completed","enrollment":" Enrollment 405","initiation":"Initiation: 12/21/2012","start_date":" 12/21/2012","primary_txt":" Primary completion: 02/16/2016","primary_completion_date":" 02/16/2016","study_txt":" Completion: 12/29/2020","study_completion_date":" 12/29/2020","last_update_posted":"2022-04-19"},{"id":"fb952a87-533f-430a-948a-d2bc777ba023","acronym":"","url":"https://clinicaltrials.gov/study/NCT02076646","created_at":"2021-01-18T09:34:17.257Z","updated_at":"2024-07-02T16:36:12.718Z","phase":"Phase 1/2","brief_title":"A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma","source_id_and_acronym":"NCT02076646","lead_sponsor":"Philogen S.p.A.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dacarbazine • darleukin (L19IL2)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 07/31/2013","start_date":" 07/31/2013","primary_txt":" Primary completion: 05/17/2016","primary_completion_date":" 05/17/2016","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2022-04-14"},{"id":"344a185c-4d14-4622-97e3-9f7082b8a174","acronym":"","url":"https://clinicaltrials.gov/study/NCT01132807","created_at":"2021-01-29T07:00:47.583Z","updated_at":"2024-07-02T16:36:29.143Z","phase":"Phase 2","brief_title":"Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","source_id_and_acronym":"NCT01132807","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 164","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2021-06-14"},{"id":"e2596bf3-613a-46c4-b272-75f27b5d410b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02501551","created_at":"2021-01-18T12:04:17.397Z","updated_at":"2024-07-02T16:36:32.374Z","phase":"Phase 2","brief_title":"Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy","source_id_and_acronym":"NCT02501551","lead_sponsor":"Yonsei University","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Stivarga (regorafenib) • dacarbazine"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2021-04-05"},{"id":"e49e1189-8eb4-4853-9809-574dc05b65a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01763164","created_at":"2021-01-17T17:33:13.221Z","updated_at":"2024-07-02T16:36:33.011Z","phase":"Phase 3","brief_title":"Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma","source_id_and_acronym":"NCT01763164","lead_sponsor":"Pfizer","biomarkers":" NRAS • RAS","pipe":" | ","alterations":" NRAS mutation • NRAS Q61","tags":["NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • NRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • dacarbazine"],"overall_status":"Completed","enrollment":" Enrollment 402","initiation":"Initiation: 07/12/2013","start_date":" 07/12/2013","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 06/04/2019","study_completion_date":" 06/04/2019","last_update_posted":"2021-03-22"},{"id":"23d1b5f3-568f-4179-a648-d998ef32d10e","acronym":"KEYNOTE 002","url":"https://clinicaltrials.gov/study/NCT01704287","created_at":"2021-01-18T07:25:04.237Z","updated_at":"2024-07-02T16:36:44.949Z","phase":"Phase 2","brief_title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)","source_id_and_acronym":"NCT01704287 - KEYNOTE 002","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • temozolomide • dacarbazine"],"overall_status":"Completed","enrollment":" Enrollment 540","initiation":"Initiation: 11/20/2012","start_date":" 11/20/2012","primary_txt":" Primary completion: 11/16/2015","primary_completion_date":" 11/16/2015","study_txt":" Completion: 01/31/2019","study_completion_date":" 01/31/2019","last_update_posted":"2020-05-18"}]